v3.26.1
Product Sales year-on-year analysis: Q2 2026 (Tables)
6 Months Ended
Jun. 30, 2026
Product Sales year-on-year analysis: Q2 2026  
Product Sales year-on-year analysis: Q2 2026

World

US

Emerging Markets

Europe

Established RoW

For the quarter ended 30 June

Change

Change

Change

Change

Change

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

Tagrisso

 

1,941

7

6

845

11

512

5

1

383

9

4

201

(3)

2

Imfinzi

 

1,854

27

27

1,054

25

211

39

36

398

39

34

191

10

17

Calquence

1,022

17

16

687

18

67

36

30

225

13

9

43

3

3

Lynparza

 

829

(1)

(3)

351

(7)

170

4

(2)

240

5

1

68

(2)

3

Enhertu

338

47

44

223

43

41

68

34

28

47

n/m

98

Zoladex

304

7

2

5

10

239

9

4

42

10

5

18

(23)

(24)

Truqap

 

233

37

37

168

18

17

n/m

n/m

34

n/m

n/m

14

77

85

Imjudo

83

(7)

(7)

51

(11)

7

(3)

(3)

14

25

20

11

(21)

(16)

Datroway

4

n/m

n/m

4

n/m

n/m

Etcamah

3

n/m

n/m

3

n/m

n/m

Other Oncology

 

102

(4)

(5)

2

58

69

(2)

(5)

4

(15)

(28)

27

(11)

(3)

Oncology

 

6,713

15

13

3,163

14

1,522

16

12

1,408

19

14

620

5

10

Farxiga

1,804

(16)

(19)

219

(48)

694

(19)

(24)

808

6

1

83

(22)

(19)

Crestor

 

331

4

1

10

(18)

299

9

5

22

(31)

(27)

Brilinta

80

(62)

(63)

2

(98)

66

5

3

11

(79)

(80)

1

(31)

(17)

Lokelma

 

221

26

26

85

13

48

47

40

47

54

46

41

12

22

Seloken

 

157

6

2

153

6

2

3

(1)

(3)

1

12

4

roxadustat

 

14

(81)

(82)

14

(81)

(82)

Wainua

70

58

58

64

50

1

n/m

n/m

4

n/m

n/m

1

n/m

n/m

Baxfendy

3

n/m

n/m

2

n/m

1

n/m

n/m

Other CVRM

 

91

(34)

(35)

(7)

n/m

70

5

2

14

(64)

(64)

14

(20)

(14)

CVRM

 

2,771

(15)

(18)

375

(44)

1,346

(11)

(15)

887

(4)

163

(16)

(12)

Symbicort

 

671

(6)

(8)

254

(20)

191

14

10

145

6

2

81

(12)

(14)

Fasenra

 

570

14

13

338

10

46

81

75

129

3

(1)

57

29

34

Breztri

346

22

20

161

9

93

43

35

62

36

31

30

23

26

Tezspire

172

54

51

24

n/m

n/m

107

49

42

41

33

41

Saphnelo

209

25

24

175

21

7

68

64

19

58

51

8

31

38

Pulmicort

 

120

13

9

2

11

97

20

15

14

(5)

(9)

7

(17)

(17)

Airsupra

 

50

19

18

45

9

5

n/m

n/m

Other R&I

 

69

13

9

7

(55)

27

(1)

(8)

33

n/m

n/m

2

6

5

R&I

 

2,207

11

9

982

490

29

24

509

21

16

226

9

11

Beyfortus

47

(52)

(52)

38

(49)

8

(66)

(67)

1

34

58

FluMist

18

79

78

(2)

n/m

1

n/m

n/m

19

90

82

Other ID

34

(31)

(34)

(1)

73

30

(20)

(26)

1

78

69

4

(68)

(66)

ID*

 

99

(37)

(38)

35

(52)

31

(18)

(24)

9

(62)

(64)

24

7

6

Ultomiris

1,314

12

12

719

8

87

42

41

307

14

9

201

12

19

Soliris

 

389

(27)

(28)

199

(29)

135

(15)

(19)

28

(50)

(50)

27

(21)

(22)

Strensiq

536

36

36

452

42

16

2

2

37

20

14

31

7

15

Koselugo

 

177

29

27

52

54

51

45

50

34

27

21

78

90

Other Rare Disease

74

36

33

30

8

13

n/m

n/m

20

11

5

11

n/m

n/m

Rare Disease

2,490

9

8

1,452

8

305

10

6

442

7

3

291

13

20

Other Medicines

230

(4)

(6)

19

(9)

166

(10)

(13)

25

52

51

20

12

14

Total Medicines

 

14,510

5

4

6,026

3

3,860

4

3,280

11

7

1,344

4

9

The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth.

* ID: Infectious Disease